Dr. Gwen Kennedy

Manager of the Immunoassay Biomarker Core Laboratory

Address:

Immunoassay Biomarker Core Laboratory,
Cardiovascular and Diabetes Medicine,
School of Medicine,
Mail Box 1,
Ninewells Hospital & Medical School,
Dundee DD1 9SY

Phone Number:

+(44) 01382 383048

Email Address:

g.y.kennedy@dundee.ac.uk

Biography

Gwen obtained her BSc in Pharmacology from University of Dundee and then went on to undertake a PhD sponsored by Pfizer Central Ltd. The title of her thesis was “Cell Adhesion Molecules: Levels, Roles and Interactions” under the supervision of Professor Jill Belch & Dr Margaret McLaren.

Gwen has had various Postdoctoral research assistant and Principal Investigator posts within the University Department of Medicine, University of Dundee funded mainly by various charities and pharmaceutical companies such as Pfizer Central Ltd. [Sandwich Kent], Scottish Heart and Arterial Risk Prevention (SHARP) [Dundee], Vasogen Ltd., [Toronto, Canada], Myalgic Encephalomyelitis Research Group for Education and support [Perth], The Institute of Cardiovascular Research (TICR) [Dundee]- research activities included investigating variations in soluble cell adhesion molecule and cytokine levels in healthy subjects and patients with various inflammatory and vascular conditions; and leukocyte/ platelet interactions by flow cytometry and other in vitro methods; interactions of leukocytes and platelets using a flow cytometer; various aspects of chronic fatigue syndrome, including inflammatory mediators, oxidative stress and apoptosis

For a couple of years Gwen was also the Chronic Fatigue Syndrome Studies Trial Manager for the Inflammatory and Diseases Research Unit, Ninewells Hospital, Dundee.

In 2005 Gwen became the Director of Thrombosis Laboratory, The Institute of Cardiovascular Research, Ninewells Hospital, Dundee and was awarded a 5 year Sir John Fisher Fellowship in 2010. 

In addition to the above post in July 2012 Gwen became the manager for the Immunoassay Biomarker Core Laboratory.

Research

Gwen’s current research is to identify new biomarkers:- with key interests to successfully stratify risk of cardiovascular disease, diabetes and inflammatory conditions in low-risk populations; to allow stratification of patient treatment therapies; and determine new platforms for biomarker discovery.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to therapeutic intervention.

As manager of the Immunoassay Biomarker Core Laboratory Gwen’s key role is to offer and provide research which supports and promotes both the School of Medicine’s mission “to understand the underlying causes of common diseases and healthcare problems - and develop interventions and therapies that will impact both patient care and quality of life”, as well as the research areas “our world class research strengths in cancer, cardiovascular disease & diabetes, informatics & public health, neuroscience and imaging”.

The Immunoassay Biomarker Core Laboratory provides immunoassay determinations in biological fluids, specimen processing, sample re-formatting and sample logistics for both internal and external collaborators. 

Publications

Gwen has over 50 peer reviewed papers and more than 40 peer reviewed published abstracts

Recent publications

Tunstall-Pedoe H, Woodward M, Hughes M, Anderson A, Kennedy G, Belch J, Kuulasmaa K, for the MORGAM Investigators. Prime mover or fellow traveller: 25-hydroxy vitamin D’s seasonal variation, cardiovascular disease, and death in the Scottish Heart Health Extended Cohort (SHHEC). International Journal of Epidemiology 2015; Advance access: 10.1093/ije/dyv092

Witham  D, Adams F, McSwiggan S, Kennedy G, Kabir G, Belch J, Khan F. High dose intermittent vitamin D3 supplementation does not improve markers of vascular function or symptoms in patients with Chronic Fatigue Syndrome- a randomized controlled trial. Nutrition Metabolism and Cardiovascular Disease 2015; 25(3): 287-94

Khan F, Ray S, Craigie AM, Kennedy G, Hill A, Barton KL, Broughton J, Belch JJF. Lowering of oxidative stress improves endothelial function in healthy subjects with habitually low intake of fruit and vegetables: a randomized controlled trial of antioxidant- and polyphenol- rich blackcurrant juice. Free Radical Biology & Medicine 2014; 72(July):232-237

Witham M, Kennedy G, Belch J, Hill A, Khan F. Association between vitamin D status and markers of vascular health in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). International Journal of Cardiology 2014; 74(1): 139-140

Witham MD, Adams F, Kabir G, Kennedy G, Belch JJF, Khan K. Effect of short-term vitamin D supplementation on markers of vascular health in South Asian Women living in the UK– a randomised controlled trial. Atherosclerosis 2013; 230: 293-299

Pauriah M, Khan F, Kim TK, Elder DH, Godfrey V, Kennedy G, Belch JJF, Booth NA, Struthers AD, Lang CC. B- type natriuretic peptide is an independent predictor of endothelial function in man. Clinical Science 2012; 123: 307-312

Kumar P, Kennedy G, Khan F, Pullar T, Belch JJF. Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scottish Medical Journal 2012; 57: 80-83

Newton D, Kennedy G, Chan K, Lang CC, Belch JJF, Khan F. “Large and small artery endothelial dysfunction in chronic fatigue syndrome". International Journal of Cardiology 2012; 154(3):335-336

Kennedy G, Underwood C, Belch JJF. The physical and functional impairment of chronic fatigue syndrome/ myalgic encephalomyelitis in childhood”. Pediatrics 2010; 125 (6); e1324-e1330

Kennedy G, Khan F, Hill A, Underwood C, Belch JJF. “Biochemical and Blood Flow Aspects of Pediatric Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis”. Archives of Pediatrics and Adolescent Medicine 2010; 164(9): 817-823

Robinson M, Gray SG, Watson MS, Kennedy G, Hill, A, Belch JJF, Nimmo MA. Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome. Scandinavian Journal of Medicine and Science in Sports 2010; 20: 282-290 

 

Selected publications prior to 2010- showing key research areas

Franklin VL, Khan F, Kennedy G, Belch JJF, Greene SA. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes.   Diabetologia 2008: 51; 353-360

Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJF. Oxidative stress levels are raised in Chronic Fatigue Syndrome and are associated with clinical symptoms. Free Radical Biology & Medicine 2005: 39; 584-589

Kennedy G, Abbot NC, Spence VA, Underwood C, Belch JJF. The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status of health in three groups of patients who fulfil the criteria. Annals of Epidemiology 2004: 14(2); 95-100

Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002: 122; 151-159

Elhadd TA, Khan F, Kirk G, McLaren M, Newton RW, Greene SA, Belch JJF. Influence of puberty on endothelial dysfunction & oxidative stress in young patients with type-1 diabetes. Diabetes Care 1998: 21; 1990-1996

Maple C, Kirk G, McLaren M, Veale D, Belch JJF. A circadian variation exists for plasma levels of intercellular adhesion molecule-1 and E-selectin in healthy volunteers. Clinical Science 1998: 94(5); 537-540

Belch JJF, Shaw JW, Kirk G, McLaren M, Robb R, Maple C, Morse P. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997: 95; 2027-2031

 

 

Teaching

Year 1 supervisor for Dundee MBChB Phase 1 Student Selected Components (SSC)